Concord Biotech Limited — Investor Meet, 19-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech reported Q2 FY26 revenue of Rs. 247 Cr (-20% YoY) and H1 FY26 revenue of Rs. 451 Cr. Performance was impacted by EU approval delays (Rs. 20-25 Cr deferred) and a postponed Middle East tender (Rs. 20 Cr). Adjusted EBITDA margin stood at 41%. Management anticipates a stronger H2 FY26, citing US tariff clarity and recovery of deferred sales. Strategic initiatives include launching a US subsidiary and investing in CAR-T cell therapy. New injectable facility costs impacted margins but is expected to contribute positively soon. The company remains confident in its long-term growth strategy.